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abstract
PURPOSE Conﬂicting evidence indicates that HIV seropositivity may inﬂuence the outcome of patients with
hepatocellular carcinoma (HCC), a leading cause of mortality in people with HIV. We aimed to verify whether HIV
affected the overall survival (OS) of patients with HCC, independent of treatment and geographic origin.
PATIENTS ANDMETHODSWe designed an international multicohort study of patients with HCC accrued from four
continents who did not receive any anticancer treatment. We estimated the effect of HIV seropositivity on
patients’ OS while accounting for common prognostic factors and demographic characteristics in uni- and
multivariable models.
RESULTS A total of 1,588 patients were recruited, 132 of whom were HIV positive. Most patients clustered within
Barcelona Clinic Liver Cancer (BCLC) C or D criteria (n = 1,168 [74%]) and Child-Turcotte-Pugh (CTP) class B
(median score, 7; interquartile range [IQR], 3). At HCC diagnosis, the majority of patients who were HIV-positive
(n = 65 [64%]) had been on antiretrovirals for a median duration of 8.3 years (IQR, 8.59 years) and had median
CD4+ cell counts of 256 (IQR, 284) with undetectable HIV RNA (n = 68 [52%]). OS decreased signiﬁcantly
throughout BCLC stages 0 to D (16, 12, 7.5, 3.1, and 3 months, respectively; P, .001). Median OS of patients
who were HIV-positive was one half that of their HIV-uninfected counterparts (2.2months [bootstrap 95%CI, 1.2
to 3.1 months] v 4.1 months [95% CI, 3.6 to 4.4 months]). In adjusted analyses, HIV seropositivity increased
the hazard of death by 24% (P = .0333) independent of BCLC (P , .0001), CTP (P , .0001), a-fetoprotein
(P , .0001), geographical origin (P , .0001), and male sex (P = .0016). Predictors of worse OS in patients
who were HIV-positive included CTP (P = .0071) and a-fetoprotein (P , .0001).
CONCLUSION Despite adequate antiretroviral treatment, HIV seropositivity is associated with decreased survival
in HCC, independent of stage, anticancer treatment, and geographical origin. Mechanistic studies investigating
the immunobiology of HIV-associated HCC are urgently required.
J Clin Oncol 37:296-304. © 2018 by American Society of Clinical Oncology
INTRODUCTION
Hepatocellular carcinoma (HCC) is the third-largest
cause of cancer-related mortality on a global scale.1 As
a recognized complication of liver cirrhosis, which
predates the onset of cancer in more than 80% of
incident cases, HCC is characterized by a wide
prognostic heterogeneity because of the combined
inﬂuence of etiology and severity of underlying chronic
liver disease and the extent of spread of malignancy.2
In people living with HIV (PLHIV), the high prevalence
of coinfection with hepatitis B virus (HBV) and C virus
(HCV) has made HCC a rapidly increasing cause of
morbidity and mortality, currently accounting for more
than 40% of liver-related deaths.3
The relative contribution of HIV to the pathogenesis
and prognosis of HCC has been the focus of intense
debate. Mechanistic evidence suggests that HIV-
mediated impairment of antiviral CD4+ and CD8+
T-cell responses facilitates an accelerated progression
of chronic liver disease to ﬁbrosis and ultimately
malignancy.4 However, more recent evidence has
highlighted how other factors, including increased
oxidative stress from combination antiretroviral therapy
(cART),5 HIV-associated gut dysbiosis,6 and the high
prevalence of excessive alcohol intake in this patient
population,7 might exert a synergistic carcinogenic role
independent of the achievement of immune recon-
stitution by optimal HIV control.
Clinical studies have been fairly inconsistent in
addressing the question of whether HIV infection
might worsen the clinical course of HCC, with some
providing null results and others suggesting evidence
of association.8-10 The reasons behind the nonuniform
conclusions regarding this prognostic relationship are
to be found in the low quality of the available evidence,
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mostly ﬂawed by the retrospective, single-center design of the
majority of studies.11 An important source of bias affecting the
currently available evidence emerges from the geographic
diversity in the provision of active anticancer treatment, which
can, in turn, lead to profound differences in clinical outcomes.
The marked heterogeneity in survival outcomes within each
Barcelona Clinic Liver Cancer (BCLC) stage is a renowned
feature of HCC12,13 and is even broader in PLHIV, where at-
tainment of long-term HIV control, polypharmacy, and socio-
economic factors might inﬂuence access and eligibility to
treatment, hence inﬂuencing patients’ survival independent of
any true immunobiologic effect of HIV.14 Understanding
whether HIV carries an independent effect on the clinical
history of HCC irrespective of treatment is an important unmet
need, with signiﬁcant ramiﬁcations in the deﬁnition of
screening, diagnosis, and treatment algorithms personalized to
the needs and clinical features of this patient population.11
To address this issue and to overcome the limitations of pre-
vious studies, we designed this large collaborative global study
to include patients from cohorts from four continents. As a
primary objective, we aimed to estimate the effect of HIV status
on the overall survival (OS) of untreated patients withHCCwhile
accounting for common prognostic factors. As a secondary
objective, we aimed to characterize prognostic factors among a
subset of patients who were HIV-positive with untreated HCC.
PATIENTS AND METHODS
Study Population
We established a global consortium of tertiary referral
centers located in North and South America and Europe to
access prospectively collected cohorts of patients who were
HIV-positive and HIV-negative with untreated HCC (Fig 1).
This multicenter effort led to the accumulation of more than
1,500 patients, resulting in, to our knowledge, the largest
observational investigation conducted to date into the effect
of HIV infection among patients with HCC.
Consecutive patient data were collected as part of routine
clinical care. Patients who were clinical trial participants
were not selected. HCC diagnosis was based on imaging or
on histologic criteria according to international guidelines.15
The Liver Cancer in HIV data set study identiﬁed all patients
diagnosed with HCC on a background of HIV infection in 44
referral centers providing specialist multidisciplinary care
for HIV and HCC across nine countries: the United States,
Canada, Brazil, Argentina, Germany, Spain, the United
Kingdom, Italy, and Australia. Consecutive referrals in the
period between 1992 and 2016 were collected using elec-
tronic case report forms in a joint database as part of an in-
ternational research consortium. At the last database update,
a total of 387 patients who were HIV-positive were identiﬁed16;
this data set was merged with a separate data set of 226 HIV-
negative controls from four centers in the United States.17
The Italian Liver Cancer (ITA.LI.CA.) data set is a multi-
center Italian collaborative network that has, to date, cu-
rated and prospectively maintained data on more than
5,000 consecutive patients evaluated in 24 tertiary referral
centers for the assessment and treatment of HCC between
the years 1988 and 2012. Before statistical analysis, the
consistency of the data was checked by the ITA.LI.CA.
study coordinator (F.T.). Outcomes pertaining to a pro-
portion of the patients presented here were published in
Included
(n = 1,588)
Patients who were HIV-negative 
included
(n = 1,456)
Patients who were HIV-positive 
included
(n = 132)
Singapore General Hospital
(n = 1,470)
ITA.LI.CA.
(n = 5,136)
Assessed for eligibility
(N = 7,219)
Excluded
  Received treatment
  Age younger than 18 years
  Unclear follow-up status
(n = 1)
(n = 1)
(n = 5,631)
(n = 5,629)
Liver cancer in HIV
(n = 613)
FIG 1. Patient accrual
to the study. ITA.LI.CA.,
Italian Liver Cancer.
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2015.18 As a separate cohort, we assessed for eligibility
1,470 patients with HCC who were diagnosed at the De-
partment of Gastroenterology and Hepatology in the Sin-
gapore General Hospital, a tertiary-level medical center in
Singapore and were listed in a prospectively maintained
HCC registry starting in January 1988.19
The primary clinical end point of the study was OS, cal-
culated from the date of diagnosis to the date of death and/
or last follow-up. Of the initial sample of 1,590 patients, we
removed one patient with unclear follow-up status and one
patient who was younger than 18 years of age.
For the full data set of 1,588 patients, we reconstructed
demographic data, complete blood count including liver
function tests, a-fetoprotein (AFP), and the international
normalized ratio value for prothrombin time from electronic
medical records. We staged patients using computerized
tomography and/or magnetic resonance imaging as clini-
cally required to derive the number of focal hepatic lesions
and maximum tumor diameter detected during contrast
enhancement. Computation of Child-Turcotte-Pugh (CTP)
functional class and BCLC stage followed standard pre-
published methodology.20
We further characterized the subset of 132 patients who
were HIV-positive in terms of prior antiretroviral treatment,
time from HCC to cART initiation, CD4+ T-cell count, HIV
viral load, hepatitis antigens and antibodies, and risk factors
for HIV infection. The study protocol was approved by the
institutional review board or ethics committee in each
participating institution and was conducted in accordance
with the Declaration of Helsinki.
Statistical Analysis
We explored the distribution of continuous variables with
median and interquartile ranges and tested differences in
medians using Mann-Whitney tests. We tabulated cate-
gorical variables and tested for differences in proportions
using Pearson’s x2 tests. We plotted the OS function by HIV
status and potential prognostic factors using Kaplan-Meier
curves. Before conducting Cox regression analyses, we
checked the proportional hazards assumption with log-
likelihood ratio tests of relevant predictors over time
bands. There was no evidence of violation at the 5% level of
the proportional hazards assumption for the main predictor
(HIV status; P = .0870). For the predictors for which the
proportional hazards assumption did not hold, we explicitly
accounted for time-dependent effects by adding interaction
terms with time bands in all regression analyses.21 We
imputed missing data using a multiple imputation with
chained equations approach, assuming that the data were
missing at random. Details are included in the Data
Supplement.
To select the main prognostic factors, we applied a
backward selection algorithm to the imputed data sets
(Data Supplement). In the full data set (N = 1,588),
backward selection identiﬁed the following prognostic
factors associated with OS at the 5% signiﬁcance level: HIV,
sex, BCLC stage, CTP class, log-transformed AFP, and
continent (a binary variable coded as North or South
America and Asia v Europe). In the subset of patients who
were HIV-positive (n = 132), two prognostic factors were
associated with OS: CTP class and log-transformed AFP.
We re-added common prognostic factors for HCC and HIV
so that the ﬁnal model for the subset of patients who were
HIV-positive included CTP class, log-transformed AFP,
BCLC stage, log-transformed HIV viral load, CD4+ con-
centration, and continent.
All reported P values are two sided. We performed all
analyses in R v.3.4.4, with the following packages: survival
v.2.42, mice v.3.0.0, and ggplot2 v.2.2.1.
RESULTS
Baseline Patient Characteristics
A total of 132 patients who were HIV-positive and 1,456
who were HIV-negative were included in the study.
Baseline features of the study cohort, stratiﬁed according to
HIV seropositivity, are presented in Table 1. On average,
patients who were HIV-positive were younger (52.9 v 66
years, P , .0001), were more commonly male (94.7% v
81.9%, P = .0003), and had a higher prevalence of HCV-
related chronic liver disease (78% v 37.1%, P , .0001)
compared with patients who were HIV-negative. Staging by
BCLC criteria (P = .93) and liver functional reserve by CTP
class (P = .34) was not different across groups; however,
patients who were HIV-positive had lower albumin (31 v
29 g/L, P, .0001) and higher ALT (56 v 47, P = .0014) and
AST (128 v 95, P = .0005) levels. The majority of patients
had a performance status of 1 (n = 534 [33.6%]) and were
classiﬁed within CTP class B criteria across HIV negativity
and HIV positivity (median score, 7; interquartile range, 3).
None of the patients infected with HCV from the ITA.LI.CA.
or Singapore General Hospital data sets had previously
been treated successfully for HCV. In terms of anti-HBV
treatment, 17 HBV carriers (2.4%) from Singapore and all
the Italian patients with chronic HBV (16% of the ITA.LI.CA.
data set) were receiving nucleoside analog therapy.
In the HIV-positive subset, 103 patients (78%) had HCV
infection. Three patients (2.9%) had received treatment
with interferon-based regimens before HCC diagnosis, and
all were nonresponders. HCV genotype was available in 53
patients (40.2%), 45 of whom (84.9%) were of genotype 1,
three (5.7%) of genotype 2, and ﬁve (9.4%) of genotype 3.
HCV RNA levels at the time of HCC diagnosis were available
in 60 patients (45.5%), with 52 (86.7%) showing evidence
of detectable viremia. In the 33 patients with HBV-
associated HCC (25%), 12 (36.4%) had evidence of de-
tectable HBV DNA levels at HCC diagnosis, and 13 (39.4%)
had received treatment for HBV infection. The majority of
patients with HIV were receiving cART (n = 85 [64.4%]),
with a median duration of treatment of 8.3 years before the
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TABLE 1. Clinicopathologic Features of Patients With Untreated Hepatocellular Carcinoma
Characteristics HIV2 (n = 1,456) HIV+ (n = 132) P
Age, years, median (IQR) 66.0 (15.79) 52.9 (10.88) , .0001*
Male sex 1,193 (81.9) 125 (94.7) .0003†
Continent: North or South America and Asia 861 (59.1) 97 (73.5) .0017†
Viral etiology of liver disease
HBV 665 (45.7) 33 (25.0) , .0001†
HCV 540 (37.1) 103 (78.0) , .0001†
Alcohol etiology of liver disease 370 (25.4) 45 (34.1) .9112 †
AFP, mg/L, median (IQR) 351.0 (6,878.00) 660.0 (9,949.50) .1116 *
Albumin, g/L, median (IQR) 31.0 (9.00) 29.0 (10.00) , .0001*
Bilirubin, mmol/L, median (IQR) 27.4 (32.49) 26.4 (42.75) .7675*
ALT, IU/L, median (IQR) 47.0 (44.00) 56.0 (56.75) .0014*
AST, IU/L, median (IQR) 95.0 (100.00) 128.0 (111.00) .0005*
Platelets, 109 cells/L, median (IQR) 149.0 (138.75) 129.0 (149.50) .0675*
Performance status
0 431 (29.6) 55 (41.7) .0048†
1 502 (34.5) 32 (24.2)
2 292 (20.1) 18 (13.6)
3 116 (8.0) 14 (10.6)
4 29 (2.0) 5 (3.8)
BCLC stage
0 15 (1.0) 2 (1.5) .9323†
A 158 (10.9) 17 (12.9)
B 191 (13.1) 16 (12.1)
C 699 (48.0) 62 (47.0)
D 372 (25.5) 35 (26.5)
CTP score, median (IQR) 7.0 (3.00) 7.0 (3.00) .4245*
CTP class
A 499 (34.3) 40 (30.3) .3435†
B 610 (41.9) 59 (44.7)
C 288 (19.8) 33 (25.0)
Maximum diameter of largest lesion, cm, median (IQR) 4.8 (5.00) 5.5 (5.25) .0493 *
Extrahepatic disease 604 (41.5) 37 (28.0) .0035†
Portal vein thrombosis 536 (36.8) 47 (35.6) .3940†
Multinodular disease 738 (46.5) 67 (50.8) .6947†
On antiretroviral treatment — 85 (64.4) —
Duration of antiretroviral treatment, years, median (IQR) 8.3 (8.59)
Antiretroviral regimen
PI — 35 (26.5) —
NNRTI — 25 (18.9) —
NRTI — 16 (12.1) —
INI — 5 (3.8) —
NNRTI + INI — 1 (0.8) —
INI + PI — 1 (0.8) —
(continued on following page)
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diagnosis of HCC. Most patients had an undetectable HIV
viral load at the time of HCC diagnosis (n = 68 [51.5%]) and
CD4 counts greater than 200 cells/mm (n = 71 [53.8%]).
The most prevalent risk factor for HIV infection was in-
travenous drug use (50%).
Relationship Between HIV and Survival of HCC
Kaplan-Meier curves (Fig 2) revealed strong evidence of
unadjusted lower survival for patients who were HIV-positive
compared with HIV-negative participants in the full sample of
1,588 patients with HCC (log-rank P , .0001). Median OS
for the whole study cohort was 4 months (bootstrap 95% CI,
3.8 to 4.1 months), with BCLC stage-speciﬁc median sur-
vivals of 16, 12, 7.5, 3.1, and 3 months for stages 0, A, B, C,
and D, respectively. At the time of analysis, 1,428 patients
(89.9%) had died. In the HIV-positive cohort, no deaths
could be attributed to HIV infection.
After adjustment for common prognostic factors andmultiple
imputation of missing data, HIV infection was independently
associated with a 24% greater hazard of death (95% CI, 2%
to 52%; P = .0333; Table 2). Other prognostic factors in-
dependently associated with OS were male sex (P = .0016),
BCLC stage, CTP class, AFP, and geographical origin (all
P , .0001). As expected, the adjusted effects estimated in
complete-case analyses (Data Supplement) were similar in
size and direction to the multiple imputation analysis.
Prognostic Factors for OS in HIV-Associated HCC
In the subset of 132 patients with HIV infection, multivariable
analyses after multiple imputation revealed two prognostic
factors to be independently associated with OS: AFP (hazard
ratio, 1.18 [95% CI, 1.09 to 1.28]; P, .0001) and CTP class
C versus A (hazard ratio, 2.78 [95% CI, 1.31 to 5.91];
P = .0079). There was no evidence of association with OS
for BCLC stage, CTP class B versus A, CD4 count, viral
load, or geographical origin. These results were in line
with those obtained from complete-case analyses (Data
Supplement).
DISCUSSION
Existing epidemiologic evidence suggests a seven-fold in-
crease in the incidence of HCC in people affected by HIV
and hepatitis compared with HIV-negative controls.22 The
excess risk associated with HIV infection has been
explained traditionally by the immunomodulatory effects of
the virus, leading to a faster progression of liver ﬁbrosis.23
Consistent with this view, people with HIV-associated HCC
present at a younger age, suggesting a shorter latency of
hepatocarcinogenesis compared with their HIV-negative
counterparts.8
Once cancer is diagnosed, however, the question as to
whether HCC arising in the context of HIV is biologically
different from other etiologies has remained unanswered.
In the absence of evidence to demonstrate potential dif-
ferences at amolecular level, clinical studies evaluating HIV
for its prognostic role in HCC have led to controversial
conclusions, with some studies demonstrating HIV to ad-
versely inﬂuence the clinical behavior of HCC and others
refuting this prognostic association.8-10,17
TABLE 1. Clinicopathologic Features of Patients With Untreated Hepatocellular Carcinoma (continued)
Characteristics HIV2 (n = 1,456) HIV+ (n = 132) P
Risk factor for HIV
Intravenous drug use — 66 (50.0) —
Heterosexual contact — 14 (10.6) —
Homosexual contact — 10 (7.6) —
Blood products — 3 (2.3) —
Unknown — 25 (18.9) —
CD4+ cell count, cells/mL, median (IQR) — 256.0 (284.00) —
Undetectable HIV viral load — 68 (51.5) —
Undetectable HBV DNA — 6 (4.5) —
Undetectable HCV RNA — 8 (6.1) —
HCV genotype
1 — 45 (34.1) —
2 — 3 (2.3) —
3 — 5 (3.8) —
NOTE. Values are No. (%) unless otherwise indicated. The sum of percentages may be less than 100% owing to missing data.
Abbreviations: AFP, a-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; CTP, Child-Turcotte-Pugh; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV+,
HIV positive; HIV2, HIV negative; INI, integrase inhibitor; IQR, interquartile range; NNRTI, nonnucleoside reverse transcription inhibitor; NRTI, nucleoside
reverse transcription inhibitor; PI, protease inhibitor.
*Mann-Whitney test.
†Pearson’s x2 test.
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In this global collaborative study, to our knowledge the
largest study to date to have evaluated the clinicopathologic
impact of HIV in patients with HCC, we demonstrate that
HIV infection adversely inﬂuences the clinical course of
HCC, leading to a 24% increase in the hazard of death
in patients who did not receive any active anticancer
treatment. A precise estimate of the relationship between
HIV and survival in patients with untreated HCC is essential
to gain insight into the natural history of the disease and to
gather basic information on patients’ prognosis that can be
used as a point of reference for future mechanistic and
clinical studies. By speciﬁcally selecting patients who did
not receive any effective anticancer treatment for HCC, we
intended to rule out the documented confounding effect
imposed by the heterogeneity in the provision of radical and
palliative therapies for HCC and to improve the quality of
evidence supporting the clinical characterization of HIV-
associated HCC.
Several previously published studies have conﬁrmed the
provision of treatment as a key prognostic factor in this
population. In the cross-sectional study by Puoti et al,9 one of
the ﬁrst to document a negative prognostic role of HIV in HCC,
60% of the patients with HIV-associated HCC received best
supportive care compared with 38% of the HIV-negative
controls (P = .02), highlighting that the adverse prognostic
role of HIV status might have been at least in part dictated by
the diverse treatment allocation across groups. Treatment
imbalance is also a feature of the study by Berretta et al,8 in
which a signiﬁcantly higher proportion of patients who were
HIV-positive received active anticancer treatment (85.6% v
65.4%, P , .001). However, despite the high proportion of
Log−rank P value < .0001
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FIG 2. Kaplan-Meier curves illustrating the prognostic relationship of
HIV seropositivity in inﬂuencing the overall survival of patients with
untreated hepatocellular carcinoma (HCC). HIV+, HIV positive; HIV2,
HIV negative.
TABLE 2. Effects of HIV+ Status and Common Prognostic Factors on Overall Survival in Multiply Imputed Data Sets
Predictor
Univariable Models Multivariable Models
Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P
Full sample of patients with HCC (n = 1,588)
HIV+ status 1.49 (1.22 to 1.82) , .0001 1.24 (1.02 to 1.52) .0333
Male sex 1.62 (1.36 to 1.94) , .0001 1.34 (1.12 to 1.61) .0016
BCLC stage C or D v 0, A, or B 3.06 (2.57 to 3.65) , .0001 1.76 (1.44 to 2.13) , .0001
CTP class
B v A 1.69 (1.45 to 1.97) , .0001 1.76 (1.50 to 2.06) , .0001
C v A 2.44 (2.04 to 2.93) , .0001 2.42 (1.98 to 2.95) , .0001
Log AFP level, ng/dL 1.18 (1.16 to 1.21) , .0001 1.15 (1.12 to 1.17) , .0001
Continent: Americas/Asia v Europe 2.59 (2.24 to 3.00) , .0001 1.92 (1.63 to 2.25) , .0001
Patients with HIV and HCC (n = 132)
BCLC stage C or D v 0, A, or B 1.58 (1.01 to 2.46) .0441 1.38 (0.82 to 2.31) .2226
CTP class
B v A 1.67 (0.86 to 3.26) .1331 1.43 (0.72 to 2.86) .3048
C v A 3.45 (1.72 to 6.92) .0005 2.78 (1.31 to 5.91) .0079
Log AFP level, ng/dL 1.20 (1.11 to 1.31) , .0001 1.18 (1.09 to 1.28) , .0001
CD4+ cell count (3 100) 0.93 (0.83 to 1.04) .1914 0.96 (0.85 to 1.08) .4689
Log HIV viral load, copies/mL 1.02 (0.96 to 1.08) .6126 0.99 (0.92 to 1.06) .7124
Continent: Americas/Asia v Europe 1.09 (0.70 to 1.69) .7154 0.90 (0.55 to 1.46) .6666
Abbreviations: AFP,a-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; CTP, Child-Turcotte-Pugh; HBV, hepatitis B virus; HCC, hepatocellular carcinoma;
HIV+, HIV positive.
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patients qualifying for radical treatments in both groups
(44.5% v 51.1%, P = .66), patients who were HIV-positive
seem disadvantaged by the inferior likelihood of receiving
treatment at recurrence (61% v 86.2%, P , .001).
Our study cohort, which included patients from multiple
centers across Europe, America, and Asia, reproduced a
balanced distribution of liver functional reserve classes and
BCLC stages, showing, perhaps unsurprisingly, that the
majority of patients who, on the basis of the opinion of the
treating multidisciplinary team, qualiﬁed solely for best
supportive care, clustered within the more advanced BCLC
stages of the disease (C and D stages [approximately
75%]). In attempting to determine the prognostic in-
teraction between HIV and the basic clinicopathologic
features of HCC, we produced a multivariable regression
model of survival to adjust our prognostic estimate for key
confounders including BCLC stage, CTP class, sex, AFP
levels. and geographical origin of the patients.
Interestingly, our results show that the effect of HIV sero-
positivity inﬂuences the survival of patients with HCC in-
dependent of a number of established staging parameters,
including BCLC stage. We also document the protective
effect of female sex18,24 in the prognosis of advanced HCC,
as well as the inherent differences in survival among
Western and Eastern populations, results that ﬁnd a strong
resonance in the HCC literature.25 Taken together, these
results suggest our patient cohort to be fully representative
of the broader, contemporary population of patients with
HCC. From an HIV infection standpoint, it is worthy of note
that the majority of the patients who were HIV-positive
considered for this study were HCV coinfected and re-
ceiving cART at the time of diagnosis and had evidence of
acceptable CD4 counts and suppressed HIV RNA levels.
This is in line with previous studies reporting on the in-
cidence and mortality of HCC in PLHIV, where HCV
coinfection is demonstrated as the predominant risk factor
for HCC,26 causing a signiﬁcant increase in liver-related
mortality even in patients achieving long-term control of the
underlying HIV infection.3 In our study, patients had been
receiving cART for a median duration of 8.3 years. However
by choosing cART initiation as a measure of duration of HIV
infection, we are likely to have underestimated the true
latency period between HIV–hepatitis coinfection and HCC
diagnosis, which typically ranges from 10 to 20 years.27
As a likely consequence of good HIV control, none of the
parameters indicative of severity of HIV infection (CD4
counts, HIV RNA) were revealed to be prognostic in our
cohort of patients with HIV-associated HCC, where liver
functional reserve and AFP levels emerged as the only
indicators of worse survival. We believe this ﬁnding to have
important ramiﬁcations regarding the clinical management
of patients with HIV-associated HCC. Clinical practice has
evolved to support an equal-access, unbiased environment
for the management of HCC in PLHIV.10 Although patients
with HCC and well-controlled HIV should face no barriers in
the provision of active anticancer treatment compared with
HIV-negative individuals, the inferior probability of survival
that accompanies patients with HIV deserves to be taken
into account in patient counseling and therapeutic decision
making.
Our study emphasizes the predominance of tumor-related
factors and hepatic reserve over parameters relating to the
severity of HIV infection in inﬂuencing survival. Several
studies have highlighted the complex and multifactorial
pathogenesis of accelerated hepatic ﬁbrosis in patients with
HIV and hepatitis. Besides viral factors, enhanced gut
permeability, metabolic dysregulation of the liver micro-
environment, and a high prevalence of concurrent liver-
speciﬁc noxae including alcohol and drug use are factors
that might explain the accelerated course of the disease.28
In our study, patients who were HIV-positive were signiﬁ-
cantly younger at HCC diagnosis and had evidence of
poorer synthetic function and more severe portal hyper-
tension as demonstrated by higher ALT and AST levels and
lower albumin and platelet counts; this suggests that the
prognostic imbalance observed might be caused by the
superadded burden of HIV infection in deteriorating pa-
tients’ liver functional reserve.16 In keeping with this view,
the balance in tumor staging features and circulating AFP
levels observed across the two patient subgroups further
emphasizes the pathophysiologic relevance of the cirrhotic
microenvironment over tumor-speciﬁc features in justifying
the excess mortality seen in HIV-associated HCC,29 where
decompensation of cirrhosis is more common and predicts
signiﬁcantly shorter survival.30
It has been shown that, particularly in the context of HIV and
HCV coinfection, patients with HCC often present with in-
ﬁltrative pattern of growth associated with a faster course of
progression and an inferior likelihood of long-term survival.27
Whether HIV infection preconditions the efﬁciency of anti-
tumor immunity, an emerging prognostic and therapeutically
actionable domain in the progression of HCC, is currently
unknown and should be investigated in future studies.
Our study acknowledges a number of limitations. First, the
patient population selected for this study consisted mostly
of patients with advanced-stage HCC, whose natural history
is fundamentally different from that of patients with early-
stage disease.31 However, as far as the primary end point of
the study is concerned, BCLC stage was balanced across
cases and controls and was accounted for in all survival
analyses. Interestingly, the survival outcomes reported in
the current study consolidate recent evidence suggesting
that the prognosis of untreated early and intermediate-
stage HCC might be signiﬁcantly poorer than reported
previously. In the study by Khalaf et al,32 median OS for
patients with BCLC 0/A and B was in fact 13 and 9 months,
respectively, signiﬁcantly shorter than the 38-, 25-, and
10-month median survival probabilities reported previously
by Giannini et al18 for BCLC 0, A, and B stages of HCC.
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Such wide interstudy variability is perhaps unsurprising if
one considers the number of potential unreported factors
that might have inﬂuenced survival estimation, including
comorbidities, socioeconomic factors, and patient pref-
erences. However, these factors are difﬁcult, if not im-
possible, to fully account for in a global multicenter study,
where access to care, availability and adherence to
screening programs, and quality of palliative care support
after diagnosis can be highly heterogeneous across
health care systems. Because we are unable to re-
construct the clinical reasons as to why patients did not
receive effective anticancer treatment, we cannot adjust
our analysis for the competing effect of liver-unrelated
predictors of survival. In particular, because of limitations
in sample size, we were unable to study the prognostic
contribution of efﬁcacious treatment of HCV or HBV on
the survival estimates we reported, a point that should be
addressed in future studies. However, the effect of
comorbidities and prior antiviral treatment is likely to be
fairly small in reality, because the dominant factor af-
fecting the mortality of this patient population is tumor
progression.33
In addition, although our study was affected by missing
data, we explicitly addressed this issue using multiple
imputation, an approach that relies on the assumption that
the data are missing at random; that is, that the missing
data mechanism does not depend on unobserved data.
The considerable amount of information available in the
data set (. 80 variables) and the large sample size
(. 1,500 patients) enabled us to include in the imputation
models all variables associated with missing data, ren-
dering the missing-at-random assumption likely to hold.
To conclude, in our global, multicenter collaborative study,
we have provided conﬁrmatory evidence to show that HIV
infection is associated with worse prognosis in a population
of patients with HCC, where survival estimates were not
biased by the effect of treatment. The median OS of patients
with HIV-associated HCC of 2.2 months reﬂects the natural
history of untreated patients seen in routine clinical practice
and should be considered a reference point for future
studies. Follow-up research should explore the prognostic
impact of socioeconomic factors and comorbid conditions,
two aspects that might be unevenly distributed across pa-
tients who were HIV-positive and HIV-negative and might
relate to the difference in survival observed in our study. In
parallel, mechanistic studies on clinical samples evaluating
the immunopathologic features of HIV-associated HCC in
comparison with HIV-negative controls are urgently required.
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